10 results on '"Tiren-Verbeet, N. L."'
Number of results to display per page
Search Results
2. Additional infusions of mesenchymal stem cells improve response rate in multidrug-resistant GvHD patients
- Author
-
Cetin, M, Akyol, G, Gonen, Z B, Keklik, M, Zararsiz, G, Unal, A, Tiren-Verbeet, N L, and Kaynar, L
- Published
- 2017
- Full Text
- View/download PDF
3. The eHealth self-management application ‘Oncokompas’ that supports cancer survivors to improve health-related quality of life and reduce symptoms:which groups benefit most?
- Author
-
van der Hout, A., Holtmaat, K., Jansen, F., Lissenberg-Witte, B. I., van Uden-Kraan, C. F., Nieuwenhuijzen, G. A.P., Hardillo, J. A., Baatenburg de Jong, R. J., Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J.E., Bosscha, K., van den Brekel, M. W.M., Petersen, J. F., Westerman, M., Honings, J., Takes, R. P., Houtenbos, I., van den Broek, W. T., de Bree, R., Jansen, P., Eerenstein, S. E.J., Leemans, C. R., Zijlstra, J. M., Cuijpers, P., van de Poll-Franse, L. V., Verdonck-de Leeuw, I. M., van der Hout, A., Holtmaat, K., Jansen, F., Lissenberg-Witte, B. I., van Uden-Kraan, C. F., Nieuwenhuijzen, G. A.P., Hardillo, J. A., Baatenburg de Jong, R. J., Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J.E., Bosscha, K., van den Brekel, M. W.M., Petersen, J. F., Westerman, M., Honings, J., Takes, R. P., Houtenbos, I., van den Broek, W. T., de Bree, R., Jansen, P., Eerenstein, S. E.J., Leemans, C. R., Zijlstra, J. M., Cuijpers, P., van de Poll-Franse, L. V., and Verdonck-de Leeuw, I. M.
- Abstract
Background: Oncokompas is a web-based self-management application that supports cancer survivors to monitor their health-related quality of life (HRQOL) and symptoms, and to obtain personalised feedback and tailored options for supportive care. In a large randomised controlled trial among survivors of head and neck cancer, colorectal cancer, and breast cancer and (non-)Hodgkin lymphoma, Oncokompas proved to improve HRQOL, and to reduce several tumour-specific symptoms. Effect sizes were however small, and no effect was observed on the primary outcome patient activation. Therefore, this study aims to explore which subgroups of cancer survivors may especially benefit from Oncokompas. Materials and methods: Cancer survivors (n = 625) were randomly assigned to the intervention group (access to Oncokompas, n = 320) or control group (6 months waiting list, n = 305). Outcome measures were HRQOL, tumour-specific symptoms, and patient activation. Potential moderators included socio-demographic (sex, age, marital status, education, employment), clinical (tumour type, stage, time since diagnosis, treatment modality, comorbidities), and personal factors (self-efficacy, personal control, health literacy, Internet use), and patient activation, mental adjustment to cancer, HRQOL, symptoms, and need for supportive care, measured at baseline. Linear mixed models were performed to investigate potential moderators. Results: The intervention effect on HRQOL was the largest among cancer survivors with low to moderate self-efficacy, and among those with high personal control and those with high health literacy scores. Cancer survivors with higher baseline symptom scores benefitted more on head and neck (pain in the mouth, social eating, swallowing, coughing, trismus), and colorectal cancer (weight) specific symptoms. Discussion: Oncokompas seems most effective in reducing symptoms in head and neck cancer and colorectal cancer survivors who report a higher burden of tumour-specific sym
- Published
- 2021
4. Reasons for not reaching or using web-based self-management applications, and the use and evaluation of Oncokompas among cancer survivors, in the context of a randomised controlled trial
- Author
-
Hout, A. van der, van Uden-Kraan, C. F., Holtmaat, K., Jansen, F., Lissenberg-Witte, B. I., Nieuwenhuijzen, G. A. P., Hardillo, J. A., Jong, R. J. Baatenburg de, Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J. E., Bosscha, K., Brekel, M. W. M. van den, Petersen, J. F., Westerman, M., Honings, J., Takes, R. P., Houtenbosq, I., Broek, W. T. van den, de Brees, R., Jansen, P., Eerenstein, S. E. J., Leemans, C. R., Zijlstrab, J. M., Cuijpers, P., Poll-Franse, L. V. van de, Leeuw, I. M. Verdonck-de, Hout, A. van der, van Uden-Kraan, C. F., Holtmaat, K., Jansen, F., Lissenberg-Witte, B. I., Nieuwenhuijzen, G. A. P., Hardillo, J. A., Jong, R. J. Baatenburg de, Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J. E., Bosscha, K., Brekel, M. W. M. van den, Petersen, J. F., Westerman, M., Honings, J., Takes, R. P., Houtenbosq, I., Broek, W. T. van den, de Brees, R., Jansen, P., Eerenstein, S. E. J., Leemans, C. R., Zijlstrab, J. M., Cuijpers, P., Poll-Franse, L. V. van de, and Leeuw, I. M. Verdonck-de
- Abstract
Introduction: The web-based self-management application Oncokompas was developed to support cancer survi-vors to monitor health-related quality of life and symptoms (Measure) and to provide tailored information (Learn) and supportive care options (Act). In a previously reported randomised controlled trial (RCT), 68% of 655 recruited survivors were eligible, and of those 45% participated in the RCT. Among participants of the RCT that were randomised to the intervention group, 52% used Oncokompas as intended. The aim of this study was to explore reasons for not participating in the RCT, and reasons for not using Oncokompas among non-users, and the use and evaluation of Oncokompas among users.
- Published
- 2021
5. The eHealth self-management application 'Oncokompas' that supports cancer survivors to improve health-related quality of life and reduce symptoms: Which groups benefit most?
- Author
-
van der Hout, A., Holtmaat, K., Jansen, F., Lissenberg-Witte, B., Van Uden-Kraan, C. F., Nieuwenhuijzen, G. A. P., Hardillo, J. A., de Jong, R. J. Baatenburg, Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J. E., Bosscha, K., van den Brekel, M. W. M., Petersen, F., Westerman, M., Honings, J., Takes, R. P., Houtenbos, null, van den Broek, W. T., de Bree, R., Jansen, P., Eerenstein, S. E. J., Leemans, C. R., Zijlstra, J. M., Cuijpersa, P., Van De Poll-Franse, L. V., Verdonck-de Leeuw, I. M., van der Hout, A., Holtmaat, K., Jansen, F., Lissenberg-Witte, B., Van Uden-Kraan, C. F., Nieuwenhuijzen, G. A. P., Hardillo, J. A., de Jong, R. J. Baatenburg, Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J. E., Bosscha, K., van den Brekel, M. W. M., Petersen, F., Westerman, M., Honings, J., Takes, R. P., Houtenbos, null, van den Broek, W. T., de Bree, R., Jansen, P., Eerenstein, S. E. J., Leemans, C. R., Zijlstra, J. M., Cuijpersa, P., Van De Poll-Franse, L. V., and Verdonck-de Leeuw, I. M.
- Abstract
BackgroundOncokompas is a web-based self-management application that supports cancer survivors to monitor their health-related quality of life (HRQOL) and symptoms, and to obtain personalised feedback and tailored options for supportive care. In a large randomised controlled trial among survivors of head and neck cancer, colorectal cancer, and breast cancer and (non-)Hodgkin lymphoma, Oncokompas proved to improve HRQOL, and to reduce several tumour-specific symptoms. Effect sizes were however small, and no effect was observed on the primary outcome patient activation. Therefore, this study aims to explore which subgroups of cancer survivors may especially benefit from Oncokompas.Materials and methodsCancer survivors (n = 625) were randomly assigned to the intervention group (access to Oncokompas, n = 320) or control group (6 months waiting list, n = 305). Outcome measures were HRQOL, tumour-specific symptoms, and patient activation. Potential moderators included socio-demographic (sex, age, marital status, education, employment), clinical (tumour type, stage, time since diagnosis, treatment modality, comorbidities), and personal factors (self-efficacy, personal control, health literacy, Internet use), and patient activation, mental adjustment to cancer, HRQOL, symptoms, and need for supportive care, measured at baseline. Linear mixed models were performed to investigate potential moderators.ResultsThe intervention effect on HRQOL was the largest among cancer survivors with low to moderate self-efficacy, and among those with high personal control and those with high health literacy scores. Cancer survivors with higher baseline symptom scores benefitted more on head and neck (pain in the mouth, social eating, swallowing, coughing, trismus), and colorectal cancer (weight) specific symptoms.DiscussionOncokompas seems most effective in reducing symptoms in head and neck cancer and colorectal cancer survivors who report
- Published
- 2021
6. The eHealth self-management application ‘Oncokompas’ that supports cancer survivors to improve health-related quality of life and reduce symptoms: which groups benefit most?
- Author
-
MS Hoofd-Hals Chirurgische Oncologie, Cancer, van der Hout, A., Holtmaat, K., Jansen, F., Lissenberg-Witte, B. I., van Uden-Kraan, C. F., Nieuwenhuijzen, G. A.P., Hardillo, J. A., Baatenburg de Jong, R. J., Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J.E., Bosscha, K., van den Brekel, M. W.M., Petersen, J. F., Westerman, M., Honings, J., Takes, R. P., Houtenbos, I., van den Broek, W. T., de Bree, R., Jansen, P., Eerenstein, S. E.J., Leemans, C. R., Zijlstra, J. M., Cuijpers, P., van de Poll-Franse, L. V., Verdonck-de Leeuw, I. M., MS Hoofd-Hals Chirurgische Oncologie, Cancer, van der Hout, A., Holtmaat, K., Jansen, F., Lissenberg-Witte, B. I., van Uden-Kraan, C. F., Nieuwenhuijzen, G. A.P., Hardillo, J. A., Baatenburg de Jong, R. J., Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J.E., Bosscha, K., van den Brekel, M. W.M., Petersen, J. F., Westerman, M., Honings, J., Takes, R. P., Houtenbos, I., van den Broek, W. T., de Bree, R., Jansen, P., Eerenstein, S. E.J., Leemans, C. R., Zijlstra, J. M., Cuijpers, P., van de Poll-Franse, L. V., and Verdonck-de Leeuw, I. M.
- Published
- 2021
7. Cost-utility of an eHealth application 'Oncokompas' that supports cancer survivors in self-management: results of a randomised controlled trial
- Author
-
CDL Patiëntenzorg KC, Anatomie, ZL Neuromusculaire Ziekten Zorg, MS Hoofd-Hals Chirurgische Oncologie, Cancer, van der Hout, A, Jansen, F, van Uden-Kraan, C F, Coupé, V M, Holtmaat, K, Nieuwenhuijzen, G A, Hardillo, J A, de Jong, R J Baatenburg, Tiren-Verbeet, N L, Sommeijer, D W, de Heer, K, Schaar, C G, Sedee, R J E, Bosscha, K, van den Brekel, M W M, Petersen, J F, Westerman, M, Honings, J, Takes, R P, Houtenbos, I, van den Broek, W T, de Bree, R, Jansen, P, Eerenstein, S E J, Leemans, C R, Zijlstra, J M, Cuijpers, P, van de Poll-Franse, L V, Verdonck-de Leeuw, I M, CDL Patiëntenzorg KC, Anatomie, ZL Neuromusculaire Ziekten Zorg, MS Hoofd-Hals Chirurgische Oncologie, Cancer, van der Hout, A, Jansen, F, van Uden-Kraan, C F, Coupé, V M, Holtmaat, K, Nieuwenhuijzen, G A, Hardillo, J A, de Jong, R J Baatenburg, Tiren-Verbeet, N L, Sommeijer, D W, de Heer, K, Schaar, C G, Sedee, R J E, Bosscha, K, van den Brekel, M W M, Petersen, J F, Westerman, M, Honings, J, Takes, R P, Houtenbos, I, van den Broek, W T, de Bree, R, Jansen, P, Eerenstein, S E J, Leemans, C R, Zijlstra, J M, Cuijpers, P, van de Poll-Franse, L V, and Verdonck-de Leeuw, I M
- Published
- 2021
8. The eHealth self-management application ‘Oncokompas’ that supports cancer survivors to improve health-related quality of life and reduce symptoms: which groups benefit most?
- Author
-
van der Hout, A., primary, Holtmaat, K., additional, Jansen, F., additional, Lissenberg-Witte, B. I., additional, van Uden-Kraan, C. F., additional, Nieuwenhuijzen, G. A. P., additional, Hardillo, J. A., additional, Baatenburg de Jong, R. J., additional, Tiren-Verbeet, N. L., additional, Sommeijer, D. W., additional, de Heer, K., additional, Schaar, C. G., additional, Sedee, R. J. E., additional, Bosscha, K., additional, van den Brekel, M. W. M., additional, Petersen, J. F., additional, Westerman, M., additional, Honings, J., additional, Takes, R. P., additional, Houtenbos, I., additional, van den Broek, W. T., additional, de Bree, R., additional, Jansen, P., additional, Eerenstein, S. E. J., additional, Leemans, C. R., additional, Zijlstra, J. M., additional, Cuijpers, P., additional, van de Poll-Franse, L. V., additional, and Verdonck-de Leeuw, I. M., additional
- Published
- 2020
- Full Text
- View/download PDF
9. Cost-utility of an eHealth application ‘Oncokompas’ that supports cancer survivors in self-management: results of a randomised controlled trial
- Author
-
van der Hout, A., primary, Jansen, F., additional, van Uden-Kraan, C. F., additional, Coupé, V. M., additional, Holtmaat, K., additional, Nieuwenhuijzen, G. A., additional, Hardillo, J. A., additional, de Jong, R. J. Baatenburg, additional, Tiren-Verbeet, N. L., additional, Sommeijer, D. W., additional, de Heer, K., additional, Schaar, C. G., additional, Sedee, R. J. E., additional, Bosscha, K., additional, van den Brekel, M. W. M., additional, Petersen, J. F., additional, Westerman, M., additional, Honings, J., additional, Takes, R. P., additional, Houtenbos, I., additional, van den Broek, W. T., additional, de Bree, R., additional, Jansen, P., additional, Eerenstein, S. E. J., additional, Leemans, C. R., additional, Zijlstra, J. M., additional, Cuijpers, P., additional, van de Poll-Franse, L. V., additional, and Verdonck-de Leeuw, I. M., additional
- Published
- 2020
- Full Text
- View/download PDF
10. Reasons for not reaching or using web-based self-management applications, and the use and evaluation of Oncokompas among cancer survivors, in the context of a randomised controlled trial.
- Author
-
van der Hout A, van Uden-Kraan CF, Holtmaat K, Jansen F, Lissenberg-Witte BI, Nieuwenhuijzen GAP, Hardillo JA, Baatenburg de Jong RJ, Tiren-Verbeet NL, Sommeijer DW, de Heer K, Schaar CG, Sedee RJE, Bosscha K, van den Brekel MWM, Petersen JF, Westerman M, Honings J, Takes RP, Houtenbos I, van den Broek WT, de Bree R, Jansen P, Eerenstein SEJ, Leemans CR, Zijlstra JM, Cuijpers P, van de Poll-Franse LV, and Verdonck-de Leeuw IM
- Abstract
Introduction: The web-based self-management application Oncokompas was developed to support cancer survivors to monitor health-related quality of life and symptoms (Measure) and to provide tailored information (Learn) and supportive care options (Act). In a previously reported randomised controlled trial (RCT), 68% of 655 recruited survivors were eligible, and of those 45% participated in the RCT. Among participants of the RCT that were randomised to the intervention group, 52% used Oncokompas as intended. The aim of this study was to explore reasons for not participating in the RCT, and reasons for not using Oncokompas among non-users, and the use and evaluation of Oncokompas among users., Methods: Reasons for not participating were assessed with a study-specific questionnaire among 243 survivors who declined participation. Usage was investigated among 320 participants randomised to the intervention group of the RCT via system data and a study-specific questionnaire that was assessed during the 1 week follow-up (T1) assessment., Results: Main reasons for not participating were not interested in participation in scientific research (40%) and not interested in scientific research and Oncokompas (28%). Main reasons for not being interested in Oncokompas were wanting to leave the period of being ill behind (29%), no symptom burden (23%), or lacking internet skills (18%). Out of the 320 participants in the intervention group 167 (52%) used Oncokompas as intended. Among 72 non-users, main reasons for not using Oncokompas were no symptom burden (32%) or lack of time (26%). Among 248 survivors that activated their account, satisfaction and user-friendliness were rated with a 7 (scale 0-10). Within 3 (IQR 1-4) sessions, users selected 32 (IQR 6-37) topics. Main reasons for not using healthcare options in Act were that the information in Learn was already sufficient (44%) or no supportive care needs (32%)., Discussion: Main reasons for not reaching or using Oncokompas were no symptom burden, no supportive care needs, or lack of time. Users selected many cancer-generic and tumour-specific topics to address, indicating added value of the wide range of available topics., Competing Interests: IMV-dL has received grants from the Dutch Cancer Society (KWF Kankerbestrijding), Pink Ribbon, the Netherlands Organization for Health Research and Development (ZonMW), the SAG Foundation–Zilveren Kruis Health Care Assurance Company, Danone Ecofund–Nutricia, Red-kite (distributor of eHealth tools), and Bristol-Myers Squibb, during the conduct of this study. CRL has received personal fees for global advisory board participation from MSD, during the conduct of this study. All other authors have no conflicts of interest., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.